ArticleFrontiers in neurology
The synergistic ototoxicity of adalimumab combined with methotrexate in the treatment of ankylosing spondylitis.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the risk of sudden sensorineural hearing loss in patients with ankylosing spondylitis receiving adalimumab in combination with methotrexate, as well as to elucidate the mechanisms underlying drug synergy and ototoxicity. Methods: A retrospective analysis was performed on data from 2,564 ankylosing spondylitis patients who were admitted to the department of rheumatology and immunology at Henan Provincial People's Hospital between 2015 and 2024. Fifty-five patients with sudden deafness were designated as the case group, while 110 matched patients without sudden deafness served as the control group. Relevant risk factors were analyzed. Drug exposure was quantified by calculating the defined daily dose (ddd), hearing classification was conducted in accordance with the latest guidelines, and confounding factors were controlled using the inverse probability weighting method (iptw). Result: The case group exhibited a longer duration of ankylosing spondylitis, with an elevated disease activity index, a higher dosage of medications administered, and an extended treatment duration ( Conclusion: The occurrence of sudden deafness in patients treated with the combination of adalimumab and methotrexate for ankylosing spondylitis is associated with drug dosage, treatment duration, and the patient's individual condition. Patients receiving high-dose, long-term therapy and those with a history of otologic conditions are exposed to an increased risk. This study elucidated the synergistic ototoxicity of combination therapy and identified risk factors for sudden deafness in patients with ankylosing spondylitis undergoing treatment with adalimumab and methotrexate, thereby providing a reference for clinical monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.